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Abstract
Cell motility and resistance to apoptosis characterize glioblastoma (GBM) growth and
malignancy. In our current work we report that galectin-1, a homodimeric adhesion mol-
ecule and carbohydrate-binding protein with afﬁnity for b-galactosides, is linked with cell
surfaceexpressionofintegrinb1andtheprocessofintegrintrafﬁcking.Usingimmunoﬂuo-
rescence, depletion of galectin-1 through both stable knockdown and transient-targeted
small interfering RNA (siRNA) treatment induces an intracellular accumulation of
integrin-b1 coincident with a diminution of integrin-b1 at points of cellular adhesion at the
cell membrane. Galectin-1 depletion does not alter the gene expression level of integrin-b1.
Transient galectin-1 depletion effectuates as well the perinuclear accumulation of protein
kinase C epsilon (PKCe) and the intermediate ﬁlament vimentin, both of which have been
shown to mediate integrin recycling in motile cells. Our results argue for the involvement of
galectin-1inthePKCe/vimentin-controlledtrafﬁckingofintegrin-b1.Theunderstandingof
molecular mediators such as galectin-1 and the pathways through which they drive the cell
invasion so descriptive of GBM is anticipated to reveal potential therapeutic targets that
promote glioma malignancy.
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INTRODUCTION
Gliomasarethemostcommonprimarybraintumors,amongwhich
glioblastoma multiforme (GBM) is the most malignant form char-
acterizedbyitsheterogeneityandaggressiveinvasivebehaviorinto
normal brain tissue; GBM is classiﬁed as World Health Organiza-
tion grade IV, and to date there is no cure (25, 26). Galectin-1 is a
multifaceted promoter of glioma malignancy (8); galectin-1 insti-
gates increased glioma invasiveness through modiﬁcations to
the actin cytoskeleton and increased Ras homolog gene family,
member A small guanosine-5′-triphosphate (GTP)ase expression
(6) and facilitates adhesion to the extracellular matrix (ECM) by
cross-linking glycoproteins (integrins) to ECM components (6).
Galectin-1 expression levels in glioma correlate directly with
tumor grade across astrocytic tumors and inversely with patient
survival in high-grade astrocytic tumors (6). Furthermore,
galectin-1expressionishigherintheinvasiveareasofglioblastoma
xenografts(5,32).Wehavepreviouslyshownthatadditionofexog-
enous galectin-1 to the culture media of U87 glioblastoma cells
stimulates cell motility, and that inhibition of galectin-1 via micro-
injection of antisense galectin-1 signiﬁcantly decreases cell motil-
ity (6). Stable knockdown of galectin-1 in U87 glioblastoma cells
alters their gene expression pattern by increasing, among other
genes, the expression of genes involved in adhesion including inte-
grin alpha 7 and integrin alpha 9 (7).
Integrins are known to play a signiﬁcant role in the progression
of cancer cell malignancy through their involvement in cell adhe-
sion, motility and intracellular signaling (1, 14, 16), with emphasis
on the role of the beta 1 integrin subunit in gliomas (2, 11, 29).
There is now much evidence to support that directed cell migration
requires the recycling of adhesion receptors through membrane
trafﬁckingpathways(9,31).Integrinsareheterodimericmembrane
spanning receptors; they consist of an a and a b subunit, each of
which traverses the membrane once with most of each polypeptide
in the extracellular space (16). Integrins are trafﬁcked ﬁrst through
an internalization step and then, after sorting at the early endo-
somes, are sent through an exocytosis pathway (9, 31). Integrin
internalization proceeds either through clathrin-mediated vesicle
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cholesterol-rich membrane domains (9, 31), and is thought to be
directed per signaling motifs on the integrin cytodomain (9, 30).
After sorting, integrins are shuttled back to the cell surface via
either the Rab4-controlled short-loop pathway, or via the Rab11
long-loop pathway that proceeds through the perinuclear recycling
complex (9, 31). Several studies have linked integrin trafﬁcking to
cell motility; many regulators of integrin trafﬁcking (including
adenosine 5′-triphosphate-ribosylation factor 6, pyruvate dehydro-
genase kinase isozyme 1 and dynamin) are found in high levels in
invadopodia (9), and increased rates of internalization and endocy-
tosis are found at the leading edge of migrating cells (9, 19).
Manyproteinkinases,aswellasmicrotubules,actinandinterme-
diate ﬁlaments act to facilitate integrin trafﬁcking (9, 19, 30, 31).
Among these, protein kinase C epsilon (PKCe) has been shown to
regulate the recycling of endocytosed integrin-b1 for return to the
plasma membrane in motile ﬁbroblast cells (17). PKCe-dependent
phosphorylation on several N-terminal serine residues of the inter-
mediate ﬁlament vimentin allows for the plasma membrane return
ofintegrin-b1(18).PKCeisanisoformofPKCandhasbeenshown
to translocate to the cell membrane at points of matrix adhesion in
HeLacells(10)andtocontributetohaptotaxis(17).
Inthisstudywedescribethegalectin-1regulationofintegrin-b1,
PKCe and vimentin localization in human glioma cells.A decrease
in galectin-1 expression induces an analogous intracellular accu-
mulation of these collaborators in receptor recycling. Here we elu-
cidate, in part, the PKCe/vimentin-dependent pathway that deﬁnes
galectin-1-mediated glioma cell migration via integrin-b1.
MATERIALS AND METHODS
Cell cultures and compounds
TheHs683[AmericanTypeCultureCollection(ATCC)codeHTB-
138],U87(ATCCcodeHTB-14),U373(ATCCcodeHTB-17)and
T98G (ATCC code CRL-1690) human GBM cell lines were
obtained from the ATCC (Manassas, VA, USA) and maintained in
our laboratory as detailed previously (5–7, 32). We also made use
of four primocultures established in our facilities as detailed previ-
ously(3).Brieﬂy,tumorspecimensweretransferredduringsurgery
intoculturemedium[RPMI-1640with20%fetalcalfserum(FCS),
1% glutamine, 1% penicillin/streptomycin; Gibco, Invitrogen,
Merelbeke, Belgium]. The tissue was minced and washed with
physiologic NaCl solution to remove red blood cells.After passage
5, cells were grown in a culture medium containing 10% FCS
without antibiotics. These primocultures have been labeled GL-5,
GL-16, GL-17 and GL-19 in the current study. They are part of a
collection of several hundreds of GBM primocultures established
attheDepartmentofNeurosurgeryoftheWagnerJaureggHospital
(Linz,Austria).
Inhibition of galectin-1 expression in human
glioblastoma cells
Transient transfection of anti-Gal1 small interfering
RNA (siRNA)
The sense sequence of the anti-Gal1 siRNA (Eurogentec,
Seraing, Belgium) used in the current work was
5′-gcugccagauggauacgaadtdt-3′ and the antisense sequence was
5′-uucguauccaucugg cagcdtdt-3′ (21, 22). A corresponding
scrambled siRNA (scr) was used as a control (sense:
5′-cuacgaugcugcuuagcucdtdt-3′ and antisense: 5′-gagcuaagc
agcaucguagdtdt-3′) (21, 22). The siRNA and scr control we made
use of in the current study have been proven to be the most efﬁcient
among several siRNAs and scr controls tested in a previous study
(21).TheantisenseandsensestrandsofthesiRNAwereannealedby
the manufacturer in 50 mM Tris, pH 7.5–8.0, 100 mM NaCl in
diethylenepyrocarbonate (DEPC)-treated water. The ﬁnal concen-
tration of siRNA duplex was 100 mM. The antisense and sense
strands of the scrambled control were annealed in the same way.
Hs683 and U87 cells were either left untreated or were transfected
with calcium phosphate (Kit ProFection® mammalian transfection
system, Promega, Leiden, the Netherlands) over 16 h with either
anti-galectin-1 siRNA or scrambled siRNA (day 0). On day 2, each
group of cells was pooled and replated either into new ﬂasks to
decrease cell conﬂuency for subsequent time points, or onto glass
coverslips to be further analyzed by immunoﬂuorescence (IF) as
detailedpreviously(21,22).Ondays5,7and9,Hs683andU87cells
were scraped into cold phosphate-buffered saline (PBS) buffer for
RNA extraction, lysed directly in boiling lysis buffer (10 mM Tris
pH 7.4, 1 mM Na3O4V, 1% sodium dodecyl sulfate, pH 7.4) for
protein extraction, or ﬁxed with 4% formalin for IF analysis.
Galectin-1 siRNA shutdown efﬁciency was conﬁrmed by both
Western blot (WB) and IF analyses (using an anti-galectin-1 anti-
bodypurchasedfromPreprotechTebuBio,Boechout,Belgium).
Stable transfection of antisense galectin-1 vectors
In addition to, but separate from the transient transfection with
anti-Galectin-1 siRNA, U87 cells were also stably transfected with
antisense galectin-1 vectors to shutdown galectin-1 expression.
TheseU87cellsthatwerestablytransfectedandusedinthecurrent
work are issued from a previous study in which the transfection
protocol and controls used are fully detailed (7).
Protein expression measurements
WB and IF analyses were performed as detailed previously (2, 21,
22).ForIF,cellswereeitherpermeabilizedwithTritonX-1000.3%
for 20 minutes in PBS + bovine serum albumin 0.1%, or left non-
permeabilized and control experiments included the omission of
the incubation step with the primary antibodies (negative control).
For WB, the integrity and equal loading of the extracts was
assessed using a tubulin antibody. For WB and IF the primary
antibodies used were as follows: anti-galectin-1 (WB dilution
1/500, IF dilution 1/100; Preprotech TebuBio), anti-integrin a9b1
(dilution 1/50; Chemicon, Biognost BVBA, Heule, Belgium), anti-
vimentin(WBdilution1/1000,IFdilution1/100;Chemicon,Biog-
nost BVBA), anti-PKCe (WB dilution 1/500, IF dilution 1/50; BD
Transduction Laboratories, Erembodegem, Belgium), and anti-
tubulin (dilution 1/2000; Abcam, Cambridge, UK). The staining
for ﬁbrillar actin was performed using ﬂuorescent phallacidin-
conjugated with Alexa Fluor 488, whereas Fluor 594-conjugated
DNaseI (Molecular Probes, Invitrogen, Merelbeke, Belgium) was
used to stain globular actin, as detailed elsewhere (6). Secondary
antibodieswerepurchasedfromPierce(PerbioScience,Erembode-
gem, Belgium) for the WBs and from Molecular Probes
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bodies).WBs were developed using the Pierce Supersignal Chemi-
luminescence system (PerbioScience).
Genomic analysis
Hs683 cells were transfected twice with scrambled (control
siRNA) or siRNA directed against galectin-1 according to the pro-
cedure detailed earlier. RNA extraction and the determination of
the quality and the integrity of the extracted RNA were assessed as
detailed elsewhere (21, 22). Full genome analysis was performed
on day 5 post-transfection at the VIB MicroArray Facility (UZ
Gasthuisberg, Catholic University of Leuven, Leuven, Belgium)
using theAffymetrix Human Genome U133 set Plus 2.0 (Affyme-
trix, High Wycombe, UK). The microarray data analysis was
carried out as detailed elsewhere (21, 22). Indeed, we used the
previous set of data from the studies detailed in Le Mercier et al
(21, 22).
Standard reverse transcription-polymerase
chain reaction (RT-PCR)
The procedure used was identical to that described previously (2,
24). RT-PCR was performed using the following primers: integrin
a9 forward 5′-tccctaaacatctctatctcc-3′ and reverse 5′-agtacgac
tttcttctttagca-3′; integrin b1 forward 5′-gactgttctttggatactagtact-3′
and reverse 5′-cagctacaattggaatgatgtc-3′; and actin forward
5′-ctaagtcatagtccgcctag-3′ and reverse 5′-aaatcgtgcgtgacattaagg-
3′.ThePCRconditionsforIntegrina9wereasfollows:predenatur-
ation, 4 minutes, 94°C; PCR ampliﬁcation, 35 cycles at 94°C, 30 s
(denaturation),59°C,30 s(annealing),72°C,1minute(extension);
andﬁnalextension:onecycleat72°C,10minutes.ThePCRcondi-
tions for integrin b1 were as follows: predenaturation, 4 minutes,
94°C; PCR ampliﬁcation, 35 cycles at 94°C, 30 s (denaturation),
58°C, 30 s (annealing), 72°C, 1 minute (extension); and ﬁnal
extension:onecycleat72°C,10minutes.Foractin,thePCRcondi-
tions were as follows: predenaturation, 4 minutes, 94°C; PCR
ampliﬁcation, 25 cycles at 94°C, 30 s (denaturation), 62°C, 30 s
(annealing), 72°C, 1 minute (extension); and ﬁnal extension: one
cycle at 72°C, 10 minutes. PCR products were resolved on a 1%
agarose gel, and visualized using Sybr Safe reagent (Invitrogen,
Eugene, OR, USA).
Quantitative RT-PCR (qRT-PCR)
The determination of integrin a9 and integrin b1 mRNA expres-
sion in three human glioma cell lines by qRT-PCR was performed
against a standard curve established through serial dilutions (108 to
102 copies/mL) of the PCR products generated with speciﬁc
primers. qRT-PCR was performed using the following primers:
integrina9forward5′-tccctaaacatctctatctcc-3′andreverse5′-tgattc
cggtgatggac-3′, and integrin b1 forward 5′-gactgttctttggat
actagtact-3′ and reverse 5′-cagctacaattggaatgatgtc-3′The quantita-
tive PCR reactions were carried out with 20 ng of puriﬁed compli-
mentary deoxyribonucleic acid in the LightCycler thermocycler
(Roche Diagnostics,Vilvoorde, Belgium) using LC-Faststart DNA
Master SYBR Green 1 (Roche Diagnostics). After ampliﬁcation,
data analysis was carried out using the “ﬁt points” algorithm of the
LightCycler quantiﬁcation software (Roche Diagnostics).
RESULTS
Galectin-1 siRNA is most effective at silencing
galectin-1 gene expression between day 5 to
day 9 post-transfection
Galectin-1-targeted siRNA was transiently transfected into both
U87 and Hs683 glioblastoma cells. Levels of intracellular
galectin-1 protein were measured by both WB and IF; galectin-1
was effectively diminished from day 5 to day 9 post-transfection in
U87 cells (Figure 1A,B) and in Hs683 cells (Figure 1C,D) in com-
parison with control and scramble-transfected cells.
Integrin-b1 is more widely expressed across
glioma cell lines than integrin-a9, and neither
the expression of integrin-b1 nor of integrin-a9
was modiﬁed following transient transfection
of siRNA targeting galectin-1
As galectin-1 has been shown to modulate glioma cell adhesion
and migration (5, 6, 32), we sought to deﬁne the relationship
between galectin-1 and the integrin most emphasized in GBM cell
migration, integrin-b1 (2, 11, 29). We obtained an antibody recog-
nizing integrin-a9/b1 and conﬁrmed that this antibody was more
speciﬁc to integrin-b1. We studied expression of each integrin
across eight glioma cell lines and found that whereas integrin-b1
was universally expressed (Figure 2A), integrin-a9 was expressed
only in the U373 andT98G cell lines (Figure 2A) by RT-PCR.This
result was further conﬁrmed by use of quantitative RT-PCR in the
Hs683, U87 and U373 glioma cell lines; integrin-b1 is expressed
among all three cell lines, whereas integrin-a9 is only expressed in
U373 and at lower levels than integrin-b1 (Figure 2B). For the
remainder of the studies we have chosen to continue with the cell
lines Hs683 and U87 to be sure that our antibody is integrin-b1
speciﬁc. We then used microarray analysis with the Affymetrix
Human Genome U133 set Plus 2.0 to determine whether transient
transfection of siRNA targeting galectin-1 affected either
integrin-a9 or integrin-b1 gene expression.Among Hs683 control,
scramble-transfected or anti-galectin-1-transfected cells, we saw
no signiﬁcant change in the gene expression of either integrin gene
(Figure 2C) indicating that galectin-1 expression levels do not
regulate the expression of integrin-b1 or integrin-a9.
In a previous study (7) we observed that long-term (several
months) knockdown of galectin-1 in U87 glioma cells increased
expression of alpha 9 integrin, whereas in the present study we did
not observe effects on integrin expression levels (including alpha
9) following short-term (several days) knockdown of galectin-1. It
thus seems that prolonged downregulation of galectin-1 in glioma
cells could be compensated by the overexpression of certain inte-
grins, including integrin-a9.
Stable and transient knockdown of galectin-1
expression leads to a loss of beta 1 integrin in
focal adhesion complexes and to an increase in
integrin b1 intracellular levels
As galectin-1 is involved in adhesion complexes (8), we asked
whether decreasing galectin-1 expression altered the pattern of
integrin expression at the leading edge of cell migration. In both
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vector we left the cells non-permeablized and co-stained them
with integrin-b1 and ﬁbrillar (polymerized) and globular (non-
polymerized) actin. In control cells, we saw integrin-b1 localiza-
tionatpointsoffocaladhesioncomplexesalongthecellmembrane
at the edge of ﬁbrillar actin staining (Figure 3Aa,Ab), whereas in
stable galectin-1 knockdown cells the cell membrane localization
of integrin-b1 was lost (Figure 3Ac). In Figure 3Aa–Ac, the red
ﬂuorescence inside the cells corresponds to globular actin (DNaseI
staining), not to integrin-b1. Thus, in comparison, we stained per-
meablized control and stable galectin-1 knockdown cells with
integrin-b1, and found that the galectin-1 knockdown cells con-
tained an intracellular accumulation of integrin-b1, with the cell
membranestainingonceagainlostincomparisonwithcontrolcells
(Figure 3Ba,Bb).
We further explored this intracellular integrin-b1 accumulation
phenomenon in both U87 and Hs683 cells transiently transfected
with scrambled or galectin-1-targeted siRNA. Similar to the
stable knockdown results, in both U87 and Hs683 cells non-
permeabilized integrin-b1 was found stained at sites of focal adhe-
sion complexes along the cell membrane of scramble-transfected
cells, a pattern that was lost in galectin-1 siRNA-transfected cells
Figure 1. Transient transfection of galectin-1 using targeted small inter-
fering RNA (siRNA) decreases intracellular galectin-1 protein. WB analy-
sis of galectin-1 expression levels at days 5, 7 and 9 post-transfection
in control (ctrl), scramble-transfected (scr), and galectin-1-transfected
(siGal1) U87 (A) and Hs683 (C) cells. Immunoﬂuorescence (IF) analysis
of galectin-1 expression levels in U87 day 7 post-transfection (B) and
Hs683 day 5 post-transfection (D) using scrambled or anti-galectin-1
siRNA. Top rows are the corresponding bright ﬁelds to the IF images.
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integrin-b1 and actin expression across eight glioma cell lines by reverse
transcription-polymerase chain reaction (RT-PCR) analysis. B. Quantita-
tive RT-PCR analysis of integrin-a9 versus integrin-b1 expression in
glioma cell lines Hs683, U87 and U373. C. Hs683 expression levels of
integrin-a9 and integrin-b1 under control (ctrl), scramble-transfected
(scr) or galectin-1 siRNA-transfected (siGal1) conditions obtained
through microarray analysis using the Affymetrix Human Genome U133
set Plus 2.0.
Figure 3. Galectin-1-targeted siRNA induces both a decrease of
integrin-b1 at the edges of the cell membrane and an increase in the
intracellular accumulation of integrin-b1. A. U87 control wild-type cells
(Aa,Ab) and U87 cells containing stably transfected antisense galectin-1
vectors (Ac) were co-stained under non-permeabilized conditions for
integrin-b1 [the red staining at the tip of actin stress ﬁbers (in green
ﬂuorescence)], ﬁbrillar actin (green) and globular actin (red staining inside
the cells). Ab. Higher magniﬁcation of the control wild-type (Aa) image.
B. U87 control wild-type cells (Ba) and U87 cells containing stably trans-
fected antisense galectin-1 vectors (Bb) were stained under permeabi-
lized conditions for integrin-b1 only (in green), without any staining to
reveal actin (Ba,Bb). C. U87 and Hs683 cells were transiently trans-
fected with either scrambled siRNA (scr) or siRNA targeted against
galectin-1 (siGal1). Cells were stained for integrin-b1 (in red) under both
permeablized and non-permeabilized conditions on either day 5 post-
transfection (Hs683) or day 7 post-transfection (U87).
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from galectin-1-stable knockdown, when U87 and Hs683 cells
were permeabilized and stained for integrin-b1, an increased intra-
cellular staining pattern was observed (Figure 3C, permeabilized).
These data show that decreasing galectin-1 expression leads to the
localization change in integrin-b1 from sites at the cell membrane
to an intracellular accumulation.
Summarizations of integrin trafﬁcking and
protein export pathways to determine potential
points of galectin-1 regulation of integrin-b1
localization
As treatment with galectin-1 siRNA causes a loss of membrane
localized and an increase in intracellular localized integrin-b1
(Figure 3),wesoughttodetermineifgalectin-1playedakeyrolein
directing either protein export pathways pertaining to integrins,
or in integrin trafﬁcking. We mapped out the processes of both
integrin trafﬁcking (Figure 4A) and of traditional protein export
(Figure 4B), and compiled a list of the major genes directing
these systems. Using the microarray analysis with the Affymetrix
Human Genome U133 set Plus 2.0 on Hs683 cells left untreated,
scramble-transfected, or transfected with siRNA targeting
galectin-1, we inquired whether decreasing galectin-1 altered the
geneexpressionofanyofthegenesonourlist.Wefoundasmallset
of genes whose expression was altered by at least 1.5-fold in either
the control versus galectin-1 siRNA ratio or in the scramble siRNA
versus galectin-1 siRNA ratio (Table 1).These data were merely to
suggestwhetherintegrintrafﬁckingand/orproteinexportpathways
may facilitate galectin-1-induced changes in integrin-b1 cellular
localization, but did not solidify any particular genes as front-
runnersforpotentialmediatorsintheseprocesses.Thesedatashow
that galectin-1-targeted siRNA alters only to a small degree the
gene expression of genes involved in integrin trafﬁcking and
protein export.
Galectin-1-targeted siRNA treatment leads to
perinuclear accumulation of both PKCe and the
intermediate ﬁlament vimentin
To begin to assess biochemically whether any of the genes whose
expression was modiﬁed upon treatment of siRNA targeting
galectin-1 were involved in integrin-b1 cellular localization
changes, we inquired if whether, similar to integrin-b1, there were
changes in the localization of the trafﬁcking and export-related
genes. Using the genes affected from the gene expression microar-
ray study under galectin-1-targeted siRNA treatment as the ﬁrst
potential candidates (Table 1), we ﬁrst selected the gene PKCe to
studyforitsknownroleinintegrin-b1trafﬁcking(17).Weassessed
through WB analysis the expression of PKCe in both U87 and
Hs683 cells under conditions of siRNA targeting galectin-1 at days
5, 7 and 9 post-transfection, and found no signiﬁcant changes in
PKCe protein expression levels (Figure 5A,B).We then performed
IF studies of PKCe localization in both U87 and Hs683 under
conditions of siRNA targeting galectin-1 at day 5 (Hs683) or day 7
(U87) post-transfection. Scramble-transfected cells showed a
diffuse staining pattern for PKCe in the cytoplasm, whereas the
localization under galectin-1 siRNA conditions shifted towards
only a strong perinuclear staining in both U87 (Figure 5C) and
Hs683 (Figure 5D) cells.
As PKCe-controlled integrin trafﬁc has been shown to require
the intermediate ﬁlament vimentin (18), we further explored the
protein expression and localization patterns of vimentin. WB
analysis of vimentin levels in U87 cells transfected with galectin-1
siRNA at days 5, 7 and 9 post-transfection revealed no change
under siRNA conditions (Figure 5A), however, vimentin levels in
similarly transfected Hs683 cells appeared to increase upon treat-
ment with siRNA-targeting galectin-1 (Figure 5B). We then per-
formed IF studies of vimentin localization in both U87 and Hs683
under conditions of siRNA targeting galectin-1 at day 5 (Hs683) or
day 7 (U87) post-transfection. We observed a similar staining phe-
nomenon as seen with PKCe; in cells treated with siRNA-targeting
galectin-1, there was an increased accumulation of perinuclear
vimentin as compared with scramble-transfected U87 (Figure 5E)
and Hs683 (Figure 5F) cells. These data show that decreasing
galectin-1 focuses the localization of both PKCe and vimentin to
the perinuclear cell region.
DISCUSSION
Our current study reports the galectin-1 regulation of integrin-b1,
PKCe and vimentin localization. We observed in both galectin-1
stable and galectin-1 transient knockdown cells a loss of
integrin-b1 on the cell membrane at points of focal adhesion
complexes coincident with an increase in intracellular levels of
integrin-b1. Integrin-b1 has been shown to play a role in glioma
malignancy; using antisense integrin-b1 mRNA, Paulus et al
showed that integrin-b1 is required for the diffuse invasion of
Figure 4. Integrin trafﬁcking and endoplasmic reticulum (ER) to Golgi
protein export pathways. A. Integrin trafﬁcking depicting the two main
pathways of internalization, clathrin-mediated and caveolar, as well as
the pathways for recycling. Clathrin-mediated internalization utilizes
clathrin coated pits, whereas caveolar internalization utilizes dynamin
GTPase to form vesicles containing lipid rafts and caveolin protein. Recy-
cling occurs through fusion to early endosomes and proceeds either via
Rab4 signaling through a short loop pathway or via Rab11 signaling
through a long loop pathway where proteins pass through the peri-
nuclear recyling complex. Respective integrins and their trafﬁcking
mediators are listed above the suggested pathways that they utilize (9,
17, 19, 30, 31). B. ER to Golgi protein export depicting coat protein
complex II (COPII)-mediated anterograde transport and coat protein
complex I (COPI)-mediated retrograde transport between the ER and the
Golgi complex. COPII assembly commences with Sar1 G-protein activa-
tion by the Sec12 guanine nucleotide exchange factor, followed by the
recruitment of the Sec23–24 heterodimer that recognizes ER export
signals on cargo proteins for inclusion in vesicles. The Sar1-Sec23–24
complex recruits the Sec13–31 heterodimer that facilitates ﬁnal budding
and vesicle formation from the ER. Vesicles proceed to the ER–Golgi
intermediate compartment (ERGIC), which is also called vesicular
tubular clusters (VTC), the complex of which transports proteins to the
Golgi destination for eventual ﬁnal export (15, 20, 23). GTP = guanosine-
5′-triphosphate; SNARE = N-ethylmaleimide-sensitive fusion protein
attachment protein receptor. PKC = protein kinase C.

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cantly change the expression of integrin-b1 in comparison with
control and scramble-transfected cells (Figure 2), the loss of mem-
brane integrin-b1 and intracellular accumulation of integrin-b1
observed in IF under galectin-1-targeted siRNA is indeed caused
byshiftsinlocalization,andnotmerelyanincreaseinexpressionof
the integrin. Galectin-1 may therefore direct, in part, malignant
progression of glioma by regulating the role of integrin-b1 through
changes in localization. Furthermore, galectin-1 has been shown in
numerous studies to bind integrin-b1, modulating adhesion and
FAK activation (13, 27, 28), and inhibiting cellular growth through
the Ras–MEK–ERK pathway (12). Galectin-1 may therefore use a
multifaceted approach in inﬂuencing integrin-b1 activity; intra-
cellular galectin-1 may work to promote integrin-b1 recycling,
and extra-cellular galectin-1 may work to promote integrin-b1-
mediated cell attachment and motility.
In this study we also reported the effects of galectin-1 depletion
on PKCe and vimentin localization. In both cell lines tested, tran-
sient transfection of siRNA-targeting galectin-1 actuated increased
perinuclear localization of both PKCe and vimentin. In galectin-1
siRNA-transfected cells, PKCe also lost the diffuse cytoplasmic
staining pattern seen in scramble-transfected cells. Although, as
stated previously (17) that PKCe has been shown to direct
integrin-b1 trafﬁcking, it has furthermore been shown to direct the
integrin-dependent adhesion and motility of human glioma cells,
inducing focal adhesion and lamellipodia formation with the sug-
gestion that the RACK1 scaffolding protein mediates integrin beta
chain interaction with activated PKCe (4). This association pro-
vides the suggestion that galectin-1 may mediate glioma invasion,
in part, through PKCe-directed integrin-b1 adhesion and motility.
Ivaska et al provided a scheme for PKCe and vimentin involve-
ment in integrin recycling whereby vimentin oligomers associate
with internalized integrin compartments allowing for both the
recruitment of PKCe and the subsequent phosphorylation of
vimentin by PKCe, the process of which leads to the release of the
vimentin-PKCe complex and the return of integrins to the plasma
membrane (18). As we have shown a perinuclear aggregation of
both PKCe and vimentin under galectin-1 depletion that is similar
to the vesicular aggregation of these two molecules seen by Ivaska
et al under inhibition of PKCe activity that, in their study, lead
to decreased integrin recycling, we can implicate galectin-1 in
mediating the PKCe–vimentin-controlled integrin-b1 recycling
pathway in glioma (18). In addition, overexpression of PKCe has
been shown in primary pediatric anaplastic astrocytoma (grade III)
tumor samples and derived cell lines, and high levels of PKCe
have been seen in both GBM (grade IV) and gliosarcoma tumor
samples, but not in pilocytic astrocytomas (grade I) (33). Similarly,
galectin-1 expression levels are signiﬁcantly higher in the diffusely
inﬁltrating astrocytic tumors than in pilocytic astrocytomas (6).
The high expression of both PKCe and galectin-1 in high-grade
glioma, and their suggested collaboration towards the malignant
phenotype, marks both molecules as exciting targets for therapeu-
tic intervention.
Although galectin-1 does appear to affect the process of
integrin-b1 recycling by inﬂuencing the localization of PKCe and
vimentin, this may not be the only mechanism that actuates
Table 1. Genes involved in integrin trafﬁcking and export whose expression is modiﬁed following galectin-1 small interfering RNA (siRNA) treatment.
Gene Name Symbol Ct: galectin-1
siRNA-transfected
(siGal1)
Scrambled
siRNA: siGal1
Coatomer protein complex, subunit alpha COPA 1, 7 1, 5
Coatomer protein complex, subunit gamma COPG 1, 5 1, 5
V-akt murine thymoma viral oncogene homolog 3 (protein
kinase B, gamma)
AKT3 1, 6 1, 7
V-akt murine thymoma viral oncogene homolog 3 (protein
kinase B, gamma)
AKT3 1, 1 1, 5
Protein kinase C, epsilon PKCe 1, 4 1, 9
SEC24-related gene family, member D (S. cerevisiae) SEC24D 3, 8 3, 1
SEC24-related gene family, member D (S. cerevisiae) SEC24D 3, 9 3, 0
SEC24-related gene family, member A (S. cerevisiae) SEC24A 1, 5 1, 5
SEC24-related gene family, member A (S. cerevisiae) SEC24A 1, 4 1, 5
SEC31-like 1 (S. cerevisiae) SEC31L1 2, 2 1, 6
SEC31-like 1 (S. cerevisiae) SEC31L1 1, 6 1, 6
SEC31-like 1 (S. cerevisiae) SEC31L1 1, 6 1, 6
RAB5A, member RAS oncogene family RAB5A 1, 5 1, 4
Figure 5. Western blot (WB) and immunoﬂuorescence (IF) analysis of
vimentin and protein kinase C epsilon (PKCe) protein expression levels;
galectin-1-targeted siRNA increases only vimentin protein levels in
Hs683, induces increased perinulear amassment of both PKCe and
vimentin, and diminishes the diffuse cytoplasmic staining of PKCe.W B
analysis of PKCe and vimentin protein expression levels in U87 (A)o r
Hs683 (B) cells untreated (ctrl), scramble-transfected (scr) or galectin-1
siRNA-transfected (siGal1) at days 5, 7 and 9 post-transfection. IF analy-
sis of PKCe localization in U87 (C) or Hs683 (D) scr or siGal1 at either day
5 (Hs683) or day 7 (U87) post-transfection. IF analysis of vimentin local-
ization in U87 (E) or Hs683 (F) cells scr or galectin-1 siRNA-transfected
(siGal1) at either day 5 (Hs683) or day 7 (U87) post-transfection. In all IF
ﬁgures right columns represent the corresponding bright ﬁeld images.
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galectin-1 conditions. The depletion of galectin-1 gene expression
levelsthroughsiRNAalsorevealedgenecandidatesinvolvedinthe
process of protein export; indeed the gene expression of Sec24, a
member of the coat protein complex II that mediates vesicle
formation in endoplasmic reticulum exit sites and transport to
vesicular-tubularclustersintheendoplasmicreticulum(ER)-Golgi
intermediate compartment (ERGIC) (Figure 4B) (15, 20, 23), is
downregulated under depleted galectin-1 conditions (Table 1).
Although Sec24 has not been shown to have speciﬁcity for mediat-
ing integrin export, depletion of Sec24 isoforms—with Sec24A
having the most signiﬁcant impact—led to disruptions in ER
export through decreased ability to recognize ER export signals on
the ERGIC-53 cargo protein (34). It is possible that galectin-1 also
workstoinﬂuenceSec24expressionandthereforeplayaroleinER
export pathways. It would be interesting to study the effect of
galectin-1 depletion on the ability of Sec24 incorporation into the
coat protein complex on vesicles forming from the ER, and on the
ability of Sec24 to read ER export signals in order to direct cargo
protein transfer to the ERGIC.
This study strengthens the role of galectin-1 in facilitating the
malignantinvasivephenotypeofglioblastoma.Galectin-1hasbeen
implicated in glioma adhesion and migration (5–7, 32), and in this
report we suggest that the galectin-1 inﬂuence on integrin-b1,
PKCe, and vimentin localization provides evidence that galectin-1
utilizes integrin trafﬁcking pathways to impel glioma malignancy.
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